These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24797319)

  • 21. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early phase dose finding methodology.
    Iasonos A; O'Quigley J
    Stat Med; 2017 Jan; 36(2):201-203. PubMed ID: 27921353
    [No Abstract]   [Full Text] [Related]  

  • 24. np1: a computer program for dose escalation strategies in phase I clinical trials.
    Kramar A; Houédé N; Paoletti X
    Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
    Seegers V; Chevret S; Resche-Rigon M
    Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A two-dimensional search algorithm for dose-finding trials of two agents.
    Lee BL; Fan SK
    J Biopharm Stat; 2012; 22(4):802-18. PubMed ID: 22651116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying a maximum tolerated contour in two-dimensional dose finding.
    Wages NA
    Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
    Su Z
    Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit.
    Whitehead J; Zhou Y; Stevens J; Blakey G; Price J; Leadbetter J
    Stat Med; 2006 Jan; 25(1):37-53. PubMed ID: 16342336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designs for phase I trials in ordered groups.
    Conaway MR; Wages NA
    Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.